Clinical Insights

Exclusive roundtable panels featuring expert voices and moderated by the Oncology Brothers—offering practical, cross-disciplinary perspectives on treatment decisions, toxicity management, and emerging issues in community care.

Breast Cancer

View All

1. OncUpdates presentation on Ribociclib and oral SERDs in high-risk cancer disease featuring expert oncologists and researchers.

Breast Cancer

01/14/2026

Ep. 4: Ribociclib and the Evolving Role of Oral SERDs in High-Risk Disease

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

OncUpdates panel discussing Abemaciclib vs Ribociclib for clinical decision-making and improving quality of life in cancer patients, featuring expert oncologists Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Laura Huppert, Dr. Komal Jhaveri, Dr. Hope Rugo, and Dr. Heather McArthur.

Breast Cancer

01/12/2026

Ep. 3: Abemaciclib vs Ribociclib: Clinical Decision-Making for Quality of Life

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

1. OncUpdates panel discussing metastatic HR+ breast cancer and CDK4/6 inhibitor treatment options with leading oncology experts.

Breast Cancer

01/10/2026

Ep. 2: Metastatic HR-Positive Breast Cancer: Choosing the Right CDK4/6 Inhibitor

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Early-Stage HR+ Breast Cancer treatment update on managing CDK4/6 inhibitor sequencing with expert physicians at OncUpdates.

Breast Cancer

01/09/2026

Ep. 4: Early-Stage HR-Positive Breast Cancer: Managing CDK4/6 Inhibitor Sequencing

Sara Hurvitz, MD, FACPSherry Shen, MDEleanora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Liver toxicity research with expert doctors discussing risk stratification and personalized adjuvant therapy in early-stage HR+ breast cancer treatment.

Breast Cancer

01/07/2026

Ep. 3: Liver Toxicity, Risk Stratification, and Personalized Adjuvant Therapy in Early-Stage HR-Positive Disease

Sara Hurvitz, MD, FACPSherry Shen, MDEleanora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

OncUpdates medical experts discussing clinical insights on optimizing Ribociclib, Abemaciclib, and Palbociclib for cancer treatment.

Breast Cancer

01/06/2026

Ep. 1: Clinical Insights: Optimizing Ribociclib, Abemaciclib, and Palbociclib Use in Metastatic HR-Positive Breast Cancer

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

1. Expert panel on practical guidance for Ribociclib and Abemaciclib in adjuvant cancer therapy, featuring leading oncologists discussing advanced treatment strategies.

Breast Cancer

01/05/2026

Ep. 2: Practical Guidance for Ribociclib and Abemaciclib in the Adjuvant Setting

Sara Hurvitz, MD, FACPSherry Shen, MDEleanora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

Adjuvant Ribociclib in early-stage HR+ breast cancer clinical insights featuring expert doctors and research leaders.

Breast Cancer

01/03/2026

Ep. 1: Adjuvant Ribociclib in Early-Stage HR-Positive Breast Cancer: Clinical Insights

Sara Hurvitz, MD, FACPSherry Shen, MDEleanora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD

1. Expert panel discusses CDK4/6 inhibitors in metastatic breast cancer at OncUpdates, featuring leading oncologists and researchers.

Breast Cancer

12/31/2025

CDK4/6 Inhibitor Selection in HR+ Metastatic Breast Cancer (Full Video)

Laura Huppert, MDKomal Jhaveri, MD, FACPHeather McArthur, MDHope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD

Adjuvant CDK4/6 therapy in early HR+ breast cancer, featuring Dr. Eleonora Teplinsky, Dr. Sherry Shen, Dr. Rahul Gosain, Dr. Sara Hurwitz, and Dr. Rohit Gosain, with clinical insights and expertise.

Breast Cancer

12/20/2025

Adjuvant Ribociclib and Abemaciclib in Early HR+ Breast Cancer (Full Video)

Eleanora Teplinsky, MDSara Hurvitz, MD, FACPSherry Shen, MDRahul Gosain, MD, MBARohit Gosain, MD

GI Oncology

View All

Panel discussion on managing toxicity and expanding RAS therapy in pancreatic cancer featuring Dr. Andrew H. Ko, Dr. Eileen O'Reilly, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Rachna Shroff, and Dr. Shu.

GI Oncology

06/16/2026

Managing Toxicity and Expanding RAS Therapy in Pancreatic Cancer

Andrew H. Ko, MDEileen O'Reilly, MDShubham Pant, MD, MBBSRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD

Panel of oncology experts discussing the clinical impact of RASolution 302 in doubling patient survival.

GI Oncology

06/15/2026

Doubling Survival: The Clinical Impact of RASolute 302

Andrew H. Ko, MDEileen O'Reilly, MDShubham Pant, MD, MBBSRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD

Panel discussion on drug development and clinical success in RAS-driven cancer, featuring experts Dr. Andrew H. Ko, Dr. Eileen O'Reilly, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Rachna Shroff, and Dr.

GI Oncology

06/14/2026

From Drug Design to Phase 3 Success in RAS-Driven Disease

Andrew H. Ko, MDEileen O'Reilly, MDShubham Pant, MD, MBBSRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBA

Panel discussion on RAS inhibitors' emerging role in pancreatic cancer featuring Dr. Michael A. Morse, Dr. Midhun Malla, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Benjamin Musher, and Dr. Janie Y. Zhang.

GI Oncology

06/13/2026

The Emerging Role of RAS Inhibitors in Pancreatic Cancer

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Dr. Andrew H. Ko, Dr. Eileen O'Reilly, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Rachna Shroff, Dr. Shubham Panti discuss Daraxonrasib's impact on pancreatic cancer survival.

GI Oncology

06/13/2026

Daraxonrasib Delivers Breakthrough Survival Gains in Pancreatic Cancer

Andrew H. Ko, MDEileen O'Reilly, MDShubham Pant, MD, MBBSRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD

Panel discussion on dose optimization and pharmacogenomic testing for pancreatic cancer treatment featuring Dr. Michael A. Morse, Dr. Midhun Malla, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Benjamin Mus.

GI Oncology

06/12/2026

Dose Optimization and Pharmacogenomic Testing in Pancreatic Cancer Treatment

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel discussion on frontline therapy options for metastatic pancreatic adenocarcinoma featuring Dr. Michael Morse, Dr. Midhun Malla, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Benjamin Musher, and Dr. J.

GI Oncology

06/06/2026

Choosing Frontline Therapy for Patients With Metastatic Pancreatic Adenocarcinoma

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of medical experts discussing frontline treatment options for metastatic pancreatic cancer, including Dr. Michael A. Morse, Dr. Midhun Malla, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Benjamin Mus.

GI Oncology

06/05/2026

Frontline Treatment Selection in Metastatic Pancreatic Cancer

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of medical experts discussing the impact of RASolute 302 on clinical practice for metastatic pancreatic ductal adenocarcinoma (PDAC).

GI Oncology

06/02/2026

Clinical Insights: Impact of RASolute 302 on Clinical Practice in Previously Treated Metastatic PDAC

Andrew H. Ko, MDShubham Pant, MD, MBBSEileen O'Reilly, MDRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD

Panel of oncology experts discussing recent advances in metastatic pancreatic cancer treatment and research.

GI Oncology

05/31/2026

Clinical Insights: Evolving Paradigms in Metastatic Pancreatic Cancer

Midhun Malla, MDMichael A. Morse, MD, FACP, MHSBenjamin Leon Musher, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of oncology experts discussing next-line treatment strategies for Durvalumab in gastric and GEJ cancer, highlighting clinical insights and practice updates.

GI Oncology

02/02/2026

Ep. 4: Next-Line Strategies and Practice Insights for Durvalumab in Gastric and GEJ Cancer

Rahul Gosain, MD, MBARohit Gosain, MDAngela Alistar, MDSteven Maron, MD, MScReetu Mukherji, MDRaji Shameem, MD

Sequencing and next steps for Zanidatamab in HER2-positive gastric cancer with expert oncologists Dr. Manish Shah, Dr. Geoffrey Ku, Dr. Nataliya Uboha, Dr. Rutika Mehta, Dr. Rohit Gosain, and Dr. Rahul Gosain.

GI Oncology

02/01/2026

Ep. 4: Sequencing and Next Steps for Zanidatamab in HER2-Positive Gastric Cancer

Rahul Gosain, MD, MBARohit Gosain, MDGeoffrey Ku, MDRutika Mehta, MD, MB, MPHManish Shah, MDNataliya Uboha, MD, PhD

1. Expert panel on balancing therapy intensity and patient tolerability in gastric cancer featuring OncUpdates specialists.

GI Oncology

01/31/2026

Ep. 3: Balancing Therapy Intensity and Patient Tolerability in Gastric and GEJ Cancer

Rahul Gosain, MD, MBARohit Gosain, MDAngela Alistar, MDSteven Maron, MD, MScReetu Mukherji, MDRaji Shameem, MD

HER2-targeted cancer treatment research panel featuring Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Nataliya Uboha, Dr. Rutika Mehta, Dr. Geoffrey Ku, and Dr. Manish Shah discussing HERZON-GEA-01 infusion and GI management for zanidatamab.

GI Oncology

01/30/2026

Ep. 3: HERIZON-GEA-01: Infusion and GI Management for Zanidatamab

Rahul Gosain, MD, MBARohit Gosain, MDGeoffrey Ku, MDRutika Mehta, MD, MB, MPHManish Shah, MDNataliya Uboha, MD, PhD

1. Upfront PD-L1 testing and perioperative immunotherapy for gastric cancer with oncology experts from OncUpdates.

GI Oncology

01/29/2026

Ep. 2: Up-Front PD-L1 Testing and Perioperative Immunotherapy in Gastric and GEJ Cancer

Rahul Gosain, MD, MBARohit Gosain, MDAngela Alistar, MDSteven Maron, MD, MScReetu Mukherji, MDRaji Shameem, MD

1. OncUpdates episode 2 featuring oncology experts discussing managing efficacy and toxicity of Zanidatamab in HER2-positive cancer.

GI Oncology

01/28/2026

Ep. 2: Managing Efficacy and Toxicity With Zanidatamab in HER2-Positive Disease

Rahul Gosain, MD, MBARohit Gosain, MDGeoffrey Ku, MDRutika Mehta, MD, MB, MPHManish Shah, MDNataliya Uboha, MD, PhD

1. Expert medical professionals discussing perioperative dervalimbal in gastric and GEJ cancer for advanced oncology treatment insights.

GI Oncology

01/27/2026

Ep. 1: Clinical Insights on Perioperative Durvalumab in Gastric and GEJ Cancer

Rahul Gosain, MD, MBARohit Gosain, MDAngela Alistar, MDSteven Maron, MD, MScReetu Mukherji, MDRaji Shameem, MD

Zanidatamab first-line therapy for HER2-positive upper GI malignancies discussed by expert panel including Dr. Geoffrey Ku, Dr. Manish Shah, Dr. Natalya Uboha, Dr. Rutika Mehta, Dr. Rohit Gosain, and Dr. Rahul Gosain.

GI Oncology

01/26/2026

Ep. 1: Zanidatamab Redefines First-Line Therapy in HER2-Positive Upper GI Malignancies

Rahul Gosain, MD, MBARohit Gosain, MDGeoffrey Ku, MDRutika Mehta, MD, MB, MPHManish Shah, MDNataliya Uboha, MD, PhD

1. OncUpdates article on perioperative Durvalumab and FLOT chemotherapy for resectable gastric and GEJ adenocarcinoma featuring expert doctors from OncUpdates.

GI Oncology

01/21/2026

Perioperative Durvalumab: The New Standard for Gastric or GEJ Cancer

Angela Alistar, MDRahul Gosain, MD, MBARohit Gosain, MDSteven Maron, MD, MScReetu Mukherji, MDRaji Shameem, MD

Zanidatamab frontline therapy for HER2-positive gastric and GEJ cancer expert panel with Dr. Rutika Mehta, Dr. Nataliya Uboha, Dr. Manish Shah, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Geoffrey Ku.

GI Oncology

01/20/2026

HERIZON-GEA-01: Zanidatamab for HER2+ Advanced Gastroesophageal Cancer

Rahul Gosain, MD, MBARohit Gosain, MDGeoffrey Ku, MDRutika Mehta, MD, MB, MPHManish Shah, MDNataliya Uboha, MD, PhD

GU Oncology

View All

Medical professionals Dr. Raji Shameem, Dr. David H. Aggen, Dr. Alexandra Drakaki, and Dr. Ashish M. Kamat discuss personalized perioperative treatment for MIBC with NIAGARA and EV-based regimens.

GU Oncology

07/31/2026

Ep. 4: Personalizing Perioperative Treatment for Muscle-Invasive Bladder Cancer With NIAGARA and EV-Based Regimens

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD

Medical professionals discussing perioperative therapy for MIBC based on patient and tumor characteristics in a hospital setting.

GU Oncology

07/30/2026

Ep. 3: Selecting Perioperative Therapy for Muscle-Invasive Bladder Cancer Based on Patient and Tumor Characteristics

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD

Medical professionals discussing perioperative MIBC interpreting pCR, survival, and treatment options in a hospital setting.

GU Oncology

07/26/2026

Ep. 2: Perioperative Muscle-Invasive Bladder Cancer: Interpreting pCR, Survival, and Treatment Selection

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD

Panel discussion on NIAGARA and EV-Based Perioperative Therapy Reshaping MIBC Treatment with Dr. Raji Shameem, Dr. David H. Aggen, Dr. Alexandra Drakaki, and Dr. Ashish M. Kamat.

GU Oncology

07/24/2026

Ep. 1: NIAGARA and EV-Based Perioperative Therapy Reshape Treatment for Muscle-Invasive Bladder Cancer

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD

Medical professionals discussing redefining perioperative bladder cancer treatment with NIAGARA in the EV + IO era.

GU Oncology

07/23/2026

Experts Review Perioperative Regimens and Potential Future Strategies for Resectable MIBC

Ashish M. Kamat, MD, MBBS, FACSDavid H. Aggen, MD, PhDAlexandra Drakaki, MD, PhDRaji Shameem, MD

Panel of medical experts discussing immunotherapy, bladder cancer, and multidisciplinary care for non-muscle invasive bladder cancer (NMIBC).

GU Oncology

06/11/2026

Real-World Integration, Immune Toxicity, and the Future of Multidisciplinary NMIBC Care

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Medical panel discussing Potomac trial results on Durvalumab and BCG therapy improving recurrence-free survival in cancer patients.

GU Oncology

06/09/2026

POTOMAC Trial Breakthrough: Durvalumab Plus BCG Shows Improved Recurrence-Free Survival

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Key oncology trial highlights Durvalumab and BCG combination improving disease-free survival, featuring experts Dr. Shilpa Gupta, Dr. Neal Shore, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Amit Patel.

GU Oncology

06/09/2026

POTOMAC Trial Breakthrough: Durvalumab Plus BCG Shows Improved Disease-Free Survival

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Panel discussion on high-risk non-muscle invasive bladder cancer (NMIBC) and BCG treatment limits featuring Dr. Shilpa Gupta, Dr. Neal Shore, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Amit Patel.

GU Oncology

06/08/2026

Defining High-Risk Non–Muscle-Invasive Bladder Cancer and the Limits of BCG Alone

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Panel of oncology experts discussing the integration of Durvalumab into non-muscle invasive bladder cancer (NMIBC) treatment strategies.

GU Oncology

06/04/2026

Clinical Insights: Integrating Durvalumab Into Non–Muscle-Invasive Bladder Cancer Care

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Advanced multidisciplinary approaches to emerging bladder cancer treatments featuring leading experts Dr. Matt Galsky, Dr. Sia Daneshmand, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Chad Reichard, and Dr.

GU Oncology

03/15/2026

Ep. 4: Multidisciplinary Approaches to Emerging Bladder Cancer Treatments

Rahul Gosain, MD, MBARohit Gosain, MDMatt Galsky, MDSia Daneshmand, MDChad Reichard, MDShilpa Gupta, MD

Advanced medical team discussing innovative approaches to perioperative ADC and immunotherapy in muscle-invasive bladder cancer.

GU Oncology

03/14/2026

Ep. 3: Optimizing Perioperative ADC and Immunotherapy in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBARohit Gosain, MDMatt Galsky, MDSia Daneshmand, MDChad Reichard, MDShilpa Gupta, MD

Advanced cancer specialists discussing systemic therapy and radical cystectomy in MIBC at OncUpdates conference. Expert panel includes Dr. Matt Galsky, Dr. Sia Daneshmand, Dr. Chad Reichard, Dr. Shilp.

GU Oncology

03/12/2026

Ep. 2: Coordinating Systemic Therapy and Radical Cystectomy in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBARohit Gosain, MDMatt Galsky, MDSia Daneshmand, MDChad Reichard, MDShilpa Gupta, MD

Shifting the Treatment Landscape in MIBC with Expert Oncologists and Innovative Approaches for Bladder Cancer Management.

GU Oncology

03/11/2026

Ep. 1: NIAGARA: Shifting the Treatment Landscape in Muscle-Invasive Bladder Cancer

Rahul Gosain, MD, MBARohit Gosain, MDMatt Galsky, MDShilpa Gupta, MDSia Daneshmand, MDChad Reichard, MD

Expert panel discussing evolving clinical insights in bladder cancer with Dr. Shilpa Gupta, Dr. Chad Reichard, Dr. Sia Daneshmand, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Matt Galsky.

GU Oncology

03/09/2026

Clinical Insights: Evolving Landscapes in MIBC and NMIBC

Rahul Gosain, MD, MBARohit Gosain, MDShilpa Gupta, MDChad Reichard, MDSia Daneshmand, MDMatt Galsky, MD

Optimizing Sequential Therapy in Advanced RCC with expert team including Dr. David Braun, Dr. Ulka Vaishampayan, Dr. Bradley McGregor, Dr. Rohit Gosain, and Dr. Rahul Gosain for oncology research and treatment advancements.

GU Oncology

12/11/2025

Ep. 5: Optimizing Sequential Therapy in Advanced RCC

Bradley McGregor, MDUlka Vaishampayan, MBBSDavid Braun, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Second-line RCC management, tolerability, comorbidities, long-term planning expert panel discussion at OncUpdates. Featuring Dr. Bradley McGregor, Dr. David Braun, Dr. Ulka Vaishampayan, Dr. Rohit Gosain, and Dr. Rahul Gosain.

GU Oncology

12/10/2025

Ep. 4: Second-Line RCC Management: Tolerability, Comorbidities, and Long-Term Planning

Ulka Vaishampayan, MBBSBradley McGregor, MDDavid Braun, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

1. OncUpdates panel discussion on balancing patient goals and efficacy in second-line RCC therapy featuring leading oncologists.

GU Oncology

12/09/2025

Ep. 3: Balancing Patient Goals and Efficacy in Second-Line RCC Therapy

David Braun, MD, PhDUlka Vaishampayan, MBBSBradley McGregor, MDRahul Gosain, MD, MBARohit Gosain, MD

VEGF TKIs in RCC research panel featuring Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. David Braun, and Dr. Bradley McGregor discussing toxicity and tolerability in renal cell carcinoma therapies.

GU Oncology

12/08/2025

Ep. 2: VEGF TKIs in RCC: Toxicity and Tolerability

David Braun, MD, PhDBradley McGregor, MDRahul Gosain, MD, MBARohit Gosain, MD

GU Oncology

12/07/2025

Ep. 1: Positioning Tivozanib in Today’s RCC Treatment Landscape

Ulka Vaishampayan, MBBSDavid Braun, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

1. OncUpdates panel discussion on treating advanced renal cell carcinoma (RCC) after first-line therapy with leading oncologists.

GU Oncology

12/06/2025

Treating Advanced RCC After First-Line Therapy (Full Video)

David Braun, MD, PhDBradley McGregor, MDUlka Vaishampayan, MBBSRahul Gosain, MD, MBARohit Gosain, MD

Expert panel discussion on cancer research and oncology advancements at OncUpdates.

GU Oncology

06/16/2025

EP. 6: Practice-Changing Insights From the NIAGARA Trial

Petros Grivas, MD, PhD

Discussion panel on oncology research at OncUpdates, featuring medical experts sharing insights on cancer treatment advancements and latest breakthroughs in oncology.

GU Oncology

06/16/2025

Ep. 5: NIAGARA Trial: Perioperative Durvalumab Enhances DFS in MIBC

Joshua Meeks, MD, PhD

Expert panel discussion on oncology research and recent advancements in cancer treatment.

GU Oncology

06/16/2025

Ep. 4: The Oncologist’s Role in Counseling Patients With MIBC Through Complex Treatment Decisions

Karine Tawagi, MD

High-level discussion on oncology research and cancer treatment advancements at OncUpdates conference. Experts share insights on innovative therapies and patient care strategies.

GU Oncology

06/16/2025

Ep. 3: Key Takeaways From the NIAGARA Trial for Patients With MIBC

Neal Shore, MD, FACS

In-depth interview with medical experts discussing latest advancements in cancer treatment and research, focusing on patient care, innovative therapies, and clinical trial updates.

GU Oncology

06/16/2025

Ep. 1: Current Treatment Strategies for Muscle-Invasive Bladder Cancer

Karine Tawagi, MD

Lecture on cancer treatment innovations discussed among medical professionals.

GU Oncology

06/16/2025

Ep. 2: Clinical Implications of Circulating Tumor DNA in MIBC

Petros Grivas, MD, PhDJoshua Meeks, MD, PhD

1. Expert oncologists presenting research on NIAGARA trial and perioperative durvalumab treatment for MIBC.

GU Oncology

06/14/2025

NIAGARA Trial: Perioperative Durvalumab for MIBC (Full Video)

Joshua Meeks, MD, PhDKarine Tawagi, MDNeal Shore, MD, FACSPetros Grivas, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

Head & neck cancers

View All

Experts discuss toxicity management and frontline evolution of Amivantamab in head and neck cancer treatment, featuring Dr. Barbara Burtness, Dr. Paul Swiecicki, and colleagues.

Head & neck cancers

06/07/2026

Toxicity Management and Frontline Evolution of Amivantamab in Head and Neck Cancer

Barbara Burtness, MDPaul Swiecicki, MDAri Rosenberg, MDJessica Geiger, MDRahul Gosain, MD, MBARohit Gosain, MD

Experts discuss Amivantamab's promising activity in heavily pretreated cancer patients, highlighting recent clinical findings and future therapeutic potential.

Head & neck cancers

06/06/2026

Amivantamab Demonstrates Promising Activity in Heavily Pretreated Disease

Barbara Burtness, MDPaul Swiecicki, MDAri Rosenberg, MDJessica Geiger, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of five medical experts discussing recurrent metastatic head and neck cancer, highlighting recent research and treatment strategies.

Head & neck cancers

06/05/2026

Defining the Current Landscape in Recurrent Metastatic Head and Neck Cancer

Barbara Burtness, MDPaul Swiecicki, MDAri Rosenberg, MDJessica Geiger, MDRahul Gosain, MD, MBARohit Gosain, MD

Expert discussion on the role of Amivantamab in treating head and neck cancer, featuring leading oncologists Dr. Barbara Burtness, Dr. Paul Swiecicki, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Ari Rosen.

Head & neck cancers

06/02/2026

Clinical Insights: Role of Amivantamab in Head and Neck Cancer

Barbara Burtness, MDAri Rosenberg, MDJessica Geiger, MDPaul Swiecicki, MDRahul Gosain, MD, MBARohit Gosain, MD

Hematology

View All

Group photo of five medical professionals discussing personalized therapy decisions in myelodysplastic syndromes.

Hematology

08/07/2026

Ep. 4: Personalizing Therapy Decisions in Lower-Risk Myelodysplastic Syndromes

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Panel of five medical experts discussing managing imetelstat toxicities in lower-risk MDS during OncUpdates episode 3.

Hematology

08/04/2026

Ep. 3: Managing Imetelstat Toxicities in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Panel of five medical experts discussing treatment sequencing in lower-risk MDS at OncUpdates.

Hematology

08/01/2026

Ep. 2: Imetelstat, Luspatercept, and ESAs: Treatment Sequencing in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Group photo of five medical professionals discussing next-generation sequencing and IPSS-M in lower-risk MDS for OncUpdates episode 1.

Hematology

07/29/2026

Ep. 1: The Growing Role of Next-Generation Sequencing and IPSS-M in Lower-Risk MDS

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

Evolving approaches in low-risk myelodysplastic syndromes with expert doctors Dr. Yasmin Abaza, Dr. Thomas LeBlanc, Dr. Hetty Carraway, Dr. Rahul Gosain, and Dr. Amer Zeidan.

Hematology

07/28/2026

The Role of Imetelstat in Lower-Risk Myelodysplastic Syndromes

Hetty Carraway, MDRahul Gosain, MD, MBAYasmin Abaza, MDThomas LeBlanc, MD, MAAmer Zeidan, MBBS, MD

OncUpdates episode 4 features experts discussing FLT3-Positive AML targeted therapy from diagnosis through long-term management.

Hematology

07/28/2026

Ep. 4: FLT3-Mutated AML: Targeted Therapy From Diagnosis Through Long-Term Management

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

OncUpdates episode 3 featuring experts discussing FLT3-mutated AML, maintenance therapy, triplet regimens, and relapse management.

Hematology

07/27/2026

Ep. 3: FLT3-Mutated AML: Maintenance Therapy, Triplet Regimens, and Relapse Management

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

Experts discuss FLT3 inhibitors expanding treatment options in acute myeloid leukemia at OncUpdates.

Hematology

07/24/2026

Ep. 2: FLT3 Inhibitors Continue to Expand Treatment Opportunities in Acute Myeloid Leukemia

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of five medical professionals discussing FLT3-mutated AML treatment strategies in a clinical setting.

Hematology

07/23/2026

Ep. 1: Optimizing FLT3-Mutated AML Through Precision Testing and Targeted Therapy

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

Group of five leukemia specialists discussing FLT3 inhibitors in AML treatment, featuring Dr. Nicholas Short, Dr. Uma Borate, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Naval Dayer.

Hematology

07/13/2026

Leukemia Specialists Review the Role of FLT3 Inhibitors Across AML Treatment Settings

Uma Borate, MBBSNaval Daver, MDNicholas Short, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel discussion on partnerships and outpatient strategies for bispecifics in multiple myeloma with Dr. S. Vincent Rajkumar, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Beth Faiman, and Dr. Rafael Fonseca.

Hematology

07/10/2026

Ep 4. Community Perspective: Partnerships and Outpatient Strategies for Bispecifics in Multiple Myeloma

Rohit Gosain, MDRahul Gosain, MD, MBAS. Vincent Rajkumar, MDRafael Fonseca, MDBeth Faiman, CNP, PhD

OncUpdates episode 3 features Dr. S. Vincent Rajkumar discussing managing side effects of BCMA bispecifics and Talquetamab in myeloma treatment.

Hematology

07/09/2026

Ep 3. Managing Side Effects BCMA Bispecifics and Talquetamab in Myeloma

Rohit Gosain, MDRahul Gosain, MD, MBAS. Vincent Rajkumar, MDRafael Fonseca, MDBeth Faiman, CNP, PhD

OncUpdates Episode 2 features Dr. S. Vincent Rajkumar discussing bispecifics: MajesTEC-3, MajesTEC-9, and MonumenTAL-3 with expert panel.

Hematology

07/08/2026

Ep 2. The Advent of Bispecifics: MajesTEC-3, MajesTEC-9, and MonumenTAL-3

Rohit Gosain, MDRahul Gosain, MD, MBAS. Vincent Rajkumar, MDRafael Fonseca, MDBeth Faiman, CNP, PhD

Dr. S. Vincent Rajkumar and colleagues discuss a new algorithm for second-line treatment of multiple myeloma in a medical webinar.

Hematology

07/07/2026

Ep 1. The New Algorithm for Second-Line Treatment of Multiple Myeloma

Rohit Gosain, MDRahul Gosain, MD, MBAS. Vincent Rajkumar, MDRafael Fonseca, MDBeth Faiman, CNP, PhD

CAR T-cell therapy in multiple myeloma with insights from ASCO 2026, featuring experts Dr. Binod Dhakal, Dr. Surbhi Sidana, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Ajai Chari.

Hematology

06/27/2026

CAR T in Myeloma: Earlier Use and Sequencing Insights from ASCO 2026

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Group of medical professionals discussing evolving treatment landscape in second-line and beyond multiple myeloma, with cityscape background.

Hematology

06/26/2026

Evolving Treatment Landscape in Second-Line and Beyond Multiple Myeloma

Beth Faiman, CNP, PhDRafael Fonseca, MDS. Vincent Rajkumar, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of four medical experts discussing managing side effects of Luspatercept in a professional setting.

Hematology

06/25/2026

Managing Side Effects of Luspatercept

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Image featuring Dr. Jamile M. Shammo, Dr. Tiffany Tanaka, Dr. Rohit Gosain, Dr. Amer Zeidan, and Dr. Christopher Benton discussing low-risk MDS and clinical trial data.

Hematology

06/24/2026

Luspatercept: Clinical Trial Data and Lessons for Low-Risk MDS

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Panel of four medical experts discussing recent advancements in defining, diagnosing, and staging myelodysplastic syndromes (MDS) for oncology updates.

Hematology

06/23/2026

Recent Advancements in Defining, Diagnosing, and Staging MDS

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Panel of four hematology experts discussing Luspatercept and low-risk MDS treatment strategies in a medical webinar.

Hematology

06/22/2026

Treating Low-Risk MDS After the Introduction of Luspatercept

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Expert panel discussing recent advances in Luspatercept treatment for LR-MDS, highlighting evolving strategies and clinical insights.

Hematology

06/12/2026

The Treatment Paradigm for Low-Risk MDS and the Impact of Luspatercept

Christopher Benton, MDJamile M. Shammo, MDTiffany Tanaka, MDAmer Zeidan, MBBS, MDRohit Gosain, MD

Group of medical professionals discussing real-world safety and care coordination for CAR T-cell therapy, featuring Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Surbhi Sidana, Dr. Ajai Chari, and Dr. Binod.

Hematology

06/12/2026

Multiple Myeloma Experts Highlight Real-World Safety and Care Coordination Following CAR T-Cell Therapy

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel discussion on treatment options and future research in polycythemia vera featuring Dr. Anand Patel, Dr. Aaron Gerds, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Anthony Hunter.

Hematology

06/11/2026

Treatment Selection and Future Directions in Polycythemia Vera

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of multiple myeloma experts discussing CAR T and BCMA therapies, including Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Surbhi Sidana, Dr. Binod Dhakal, and Dr. Ajai Chari, during a virtual conferenc.

Hematology

06/11/2026

CAR T vs BCMA-Directed Bispecific Antibodies: Multiple Myeloma Experts Share Sequencing Insights

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of four doctors discussing molecular responses and long-term disease control in polycythemia vera, highlighting recent research and treatment strategies.

Hematology

06/10/2026

Molecular Responses and Long-Term Disease Control in Polycythemia Vera

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

$Innovative CAR T-cell therapy for relapsed or refractory multiple myeloma, featuring expert insights from Dr. Surbhi Sidana, Dr. Rahul Gosain, Dr. Ajai Chari, and Dr. Binod Dhakal.$

Hematology

06/10/2026

CAR T-Cell Therapy Moves Earlier in Relapsed/Refractory Multiple Myeloma

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of four doctors discussing treatment strategies for polycythemia vera, focusing on optimizing ropeginterferon therapy, with a city skyline background.

Hematology

06/09/2026

Optimizing Ropeginterferon Use in Polycythemia Vera

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of four doctors discussing current treatment paradigms and the emerging role of Ropiginterferon in polycythemia vera (PV) at OncUpdates.

Hematology

06/08/2026

Current Treatment Paradigms and the Emerging Role of Ropeginterferon Alfa-2b-njft in PV

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

Close-up of Verenzo (bevemacil) 50 mg tablets in packaging, used for erectile dysfunction treatment, displayed on a white background.

Hematology

06/05/2026

CAR T in Myeloma: Earlier Use and Sequencing Insights from ASCO 2026

Binod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD

Experts discuss the role of Ropoginterferon Alfa-2b in treating Polycythemia Vera, highlighting recent clinical insights and therapeutic strategies.

Hematology

05/31/2026

Clinical Insights: Role of Ropeginterferon Alfa-2b-njft in Polycythemia Vera

Aaron Gerds, MDAnthony M. Hunter, MDAnand Patel, MDRahul Gosain, MD, MBARohit Gosain, MD

1. Expert panel discussing managing fatigue and phlebotomy burden in pulmonary embolism patients using Rusteride at OncUpdates conference.

Hematology

01/10/2026

Ep. 4: Managing Fatigue and Phlebotomy Burden in PV With Rusfertide

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

Managing Hematocrit and Symptoms in PV: Dose Titration Strategies for Rusfertide.

Hematology

01/08/2026

Ep. 3: Managing Hematocrit and Symptoms in PV: Dose-Titration Strategies for Rusfertide

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

1. A group of medical researchers and doctors discussing cancer treatment algorithms in a professional conference setting.

Hematology

01/06/2026

Ep. 2: Integrating Rusfertide Into the Polycythemia Vera Treatment Algorithm

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

1. Innovative hematocrit control approaches in polycythemia vera presented by leading oncology experts for improved patient management.

Hematology

01/02/2026

Ep. 1: Clinical Insights: New Approaches to Hematocrit Control in Polycythemia Vera

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

Polycythemia Vera management insights, hematocrit control, and clinical treatment strategies by Dr. Andrew Kuykendall, Dr. Aaron Gerds, Dr. Talha Badar, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Hematology

12/22/2025

Clinical Insights: VERIFY Trial Shows Rusfertide’s Potential to Transform PV Treatment (Full Video)

Talha Badar, MBBS, MDAaron Gerds, MDAndrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD

Lung Cancer

View All

Panel of four doctors discussing biomarker testing and safety in HER2-mutated non-small cell lung cancer during Ep. 4 of OncUpdates.

Lung Cancer

07/29/2026

Ep. 4: Biomarker Testing and Safety Considerations in HER2-Mutated NSCLC

Charu Aggarwal, MD, MPHSamuel Caughron, MDPaolo Tarantino, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel discussion on T-DXd in HER2-mutated and HER2-expressing cancers featuring Dr. Charu Aggarwal, Dr. Paolo Tarantino, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Samuel Caughron.

Lung Cancer

07/25/2026

Ep. 3: Clinical Insights: The Evolving Role of T-DXd in HER2-Mutated and HER2-Expressing Cancers

Charu Aggarwal, MD, MPHSamuel Caughron, MDPaolo Tarantino, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of four doctors discussing HER2-positive NSCLC treatment options in a medical webinar.

Lung Cancer

07/23/2026

Ep. 2: T-DXd Expands Treatment Opportunities for HER2-Positive NSCLC

Charu Aggarwal, MD, MPHSamuel Caughron, MDPaolo Tarantino, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel of five doctors discussing HER2 testing in non-small cell lung cancer for OncUpdates.

Lung Cancer

07/22/2026

Ep. 1: HER2 Testing Continues to Evolve in Non–Small Cell Lung Cancer

Charu Aggarwal, MD, MPHSamuel Caughron, MDPaolo Tarantino, MDRahul Gosain, MD, MBARohit Gosain, MD

Group of four doctors discussing HER2 testing and treatment options for lung cancer at a medical conference.

Lung Cancer

07/16/2026

Multidisciplinary Team Discusses Diagnosing and Treating HER2–Positive NSCLC

Charu Aggarwal, MD, MPHSamuel Caughron, MDPaolo Tarantino, MDRahul Gosain, MD, MBARohit Gosain, MD

Panel discussion on toxicity, patient selection, and future of Ivonescimab with Dr. Bo Wang, Dr. Benjamin P. Levy, and Dr. Jarushka Naidoo.

Lung Cancer

06/23/2026

Balancing Efficacy and Safety: Toxicity, Patient Selection, and the Future of Ivonescimab

Benjamin Levy, MDJarushka Naidoo, MB, BCh, MHSBo Wang, MD

Diverse group of medical professionals discussing gender representation and applicability of HARMONi-6 findings in oncology research.

Lung Cancer

06/22/2026

Gender Representation and Global Applicability of the HARMONi-6 Findings

Benjamin Levy, MDJarushka Naidoo, MB, BCh, MHSBo Wang, MD

Image from OncUpdates showing Dr. Bo Wang, Dr. Benjamin P. Levy, and Dr. Jarushka Naidoo discussing age-related findings from the HARMONi-6 trial.

Lung Cancer

06/21/2026

Age-Related Findings and Subgroup Analyses From the HARMONi-6 Trial

Benjamin Levy, MDJarushka Naidoo, MB, BCh, MHSBo Wang, MD

Image from OncUpdates showing Dr. Bo Wang, Dr. Benjamin P. Levy, and Dr. Jarushka Naidoo discussing HARMONi-6 trial results.

Lung Cancer

06/20/2026

Follow-Up Duration and Survival Trends in the HARMONi-6 Trial

Benjamin Levy, MDJarushka Naidoo, MB, BCh, MHSBo Wang, MD

Group photo of three doctors discussing HARMONi-6 as a new option for squamous NSCLC in a clinical setting.

Lung Cancer

06/19/2026

HARMONi-6 Generates Enthusiasm as a Potential New Option for Squamous NSCLC

Benjamin Levy, MDJarushka Naidoo, MB, BCh, MHSBo Wang, MD

Image showing Dr. Bo Wang, Dr. Benjamin P. Levy, and Dr. Jarushka Naidoo discussing dual PD-1/VEGF blockade in squamous lung cancer research.

Lung Cancer

06/18/2026

Clinical Insights: The HARMONi-6 Trial and Dual PD-1/VEGF Blockade in Squamous Lung Cancer

Benjamin Levy, MDJarushka Naidoo, MB, BCh, MHSBo Wang, MD

Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC - OncUpdates featuring Dr. Julia Rotow, Dr. Fawzi Abu Rous, Dr. Sarah Goldberg, and Dr. Susan Scott discussing recent advances in.

Lung Cancer

03/19/2026

Ep. 3: Time Toxicity, CNS Risk, and Sequencing Strategy in EGFR-Mutant NSCLC

Eric Singhi, MDSarah Goldberg, MD, MPHFawzi Abu Rous, MDJulia Rotow, MDSusan Scott, MD

Proactive toxicity management and CNS control in EGFR-mutant NSCLC discussed by leading oncologists at OncUpdates conference. Expert insights on personalized treatment strategies.

Lung Cancer

03/17/2026

Ep. 2: Clinical Insights: Proactive Toxicity Management and CNS Control in EGFR-Mutant NSCLC

Eric Singhi, MDSarah Goldberg, MD, MPHSusan Scott, MDFawzi Abu Rous, MDJulia Rotow, MD

Accelerated cancer treatment strategies and CNS management in EGFR-mutant NSCLC featuring experts Chinmay Jani, MD, and Luis Raez, MD, at OncUpdates conference.

Lung Cancer

03/15/2026

Ep. 3: Intensification Strategies and CNS Management in EGFR-Mutant NSCLC

Chinmay Jani, MDLuis Raez, MD, FACP, FCCP, FASCO

OS Benefit and Patient-Centered Delivery Advances in EGFR-Positive NSCLC, featuring Dr. Eric Singhi, Dr. Julia Rotow, Dr. Susan Scott, Dr. Sarah Goldberg, and Dr. Fawzi Abu Rous discussing recent onco.

Lung Cancer

03/14/2026

Ep. 1: OS Benefit and Patient-Centered Delivery Advances in EGFR-Mutant NSCLC

Eric Singhi, MDSusan Scott, MDSarah Goldberg, MD, MPHFawzi Abu Rous, MDJulia Rotow, MD

Advanced medical professionals Luis Raez, MD, and Chinmay Jani, MD, discuss the latest advancements in subcutaneous Amivantamab reshaping frontline EGFR-mutant NSCLC care.

Lung Cancer

03/13/2026

Ep. 2: Subcutaneous Amivantamab Reshapes Frontline EGFR-Mutant NSCLC Care

Chinmay Jani, MDLuis Raez, MD, FACP, FCCP, FASCO

Overcoming infusion barriers in EGFR-mutant non-small cell lung cancer with expert insights from Luis Raez, MD, and Chinmay Jani, MD, at OncUpdates conference.

Lung Cancer

03/11/2026

Ep. 1: Overcoming Infusion Barriers in EGFR-Mutant Non–Small Cell Lung Cancer

Chinmay Jani, MDLuis Raez, MD, FACP, FCCP, FASCO

CNS activity and sequencing strategies for Dato-DXd in EGFR-mutated NSCLC featuring expert oncologists from OncUpdates.

Lung Cancer

01/14/2026

Ep. 5: CNS Activity and Sequencing Strategies for Datopotamab Deruxtecan in EGFR-Mutant NSCLC

Aaron Lisberg, MDSarah Sunshine, MDBlanca Ledezma, NPRahul Gosain, MD, MBARohit Gosain, MD

1. Expert oncologists Dr. Aaron Lisberg, Dr. Sarah Sunshine, Dr. Blanca Ledezma, Dr. Rahul Gosain, and Dr. Rohit Gosain discuss Dato-DXd in EGFR-Mutant NSCLC for community-based monitoring and toxicity management.

Lung Cancer

01/13/2026

Ep. 4: Datopotamab Deruxtecan in EGFR-Mutated NSCLC: Community-Based Monitoring and Toxicity Management

Aaron Lisberg, MDSarah Sunshine, MDBlanca Ledezma, NPRahul Gosain, MD, MBARohit Gosain, MD

1. Expert oncology researchers discussing monitoring, dosing, and rechallenge strategies in EGFR-mutated NSCLC during a conference panel.

Lung Cancer

01/12/2026

EP. 3: Monitoring, Dosing, and Rechallenge Strategies With Datopotamab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Aaron Lisberg, MDSarah Sunshine, MDBlanca Ledezma, NPRahul Gosain, MD, MBARohit Gosain, MD

1. Expert oncology panel discussing practical strategies for managing ocular, oral, and pulmonary toxicities with Dato-DXd in cancer treatment.

Lung Cancer

01/11/2026

Ep. 2: Managing Ocular Toxicity, Mucositis, and ILD With Datopotamab Deruxtecan in EGFR-Mutated NSCLC

Aaron Lisberg, MDSarah Sunshine, MDBlanca Ledezma, NPRahul Gosain, MD, MBARohit Gosain, MD

1. Team of medical researchers and oncologists discussing efficacy, safety, and management of data-driven targeted therapy (DAtDX) in EGFR-mutated lung cancer.

Lung Cancer

01/09/2026

Ep. 1: Efficacy, Safety, and Management of Dato-DXd in EGFR-Mutated Lung Cancer

Aaron Lisberg, MDSarah Sunshine, MDBlanca Ledezma, NPRahul Gosain, MD, MBARohit Gosain, MD

1. Expert medical team discussing clinical insights on Dato-DXd in EGFR-mutated NSCLC for oncology research and treatment advancements.

Lung Cancer

12/31/2025

Multidisciplinary Strategies for Dato-DXd in Pretreated EGFR-Mutated Advanced NSCLC (Full Video)

Aaron Lisberg, MDSarah Sunshine, MDBlanca Ledezma, NPRahul Gosain, MD, MBARohit Gosain, MD

1. OncUpdates panel featuring leading oncologists discussing advances in EGFR-Mutant NSCLC treatment strategies.

Lung Cancer

12/30/2025

EP. 5: Closing Perspectives on Advancing Care in EGFR-Positive NSCLC

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

Advances in managing toxicities in Mariposa including IRRs, VTEs, and rash with expert strategies by Dr. Joshua Sabari, Dr. Danny Nguyen, Dr. Alexander Spira, and Dr. Edgardo Santos, featured on OncUpdates.

Lung Cancer

12/29/2025

Ep. 4: Managing Toxicities in MARIPOSA: Mitigating Treatment-Related Adverse Events

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

OncUpdates panel discussing clinical insights on escalation versus de-escalation in EGFR-positive NSCLC with doctors Joshua Sabari, Danny Nguyen, Alexander Spira, Edgardo Santos, and Eric Singhi.

Lung Cancer

12/27/2025

Ep. 3: Clinical Insights: Escalation vs De-escalation in EGFR-Positive NSCLC

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

1. Expert panel on CNS activity and resistance discussing Amivantamab and Lazertinib for cancer treatment with Dr. Joshua Sabari, Dr. Edgardo Santos, Dr. Eric Singhi, and Dr. Alexander Spira.

Lung Cancer

12/21/2025

Ep. 2: CNS Control and Resistance: Panel Examines Amivantamab Plus Lazertinib

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

EGFR-Mutant NSCLC survival updates featuring experts Dr. Danny Nguyen, Dr. Eric Singhi, Dr. Alexander Spira, Dr. Edgardo Santos, and Dr. Joshua Sabari discussing Mariposa & FLAURA2 studies.

Lung Cancer

12/19/2025

Ep. 1: Overall Survival Updates in EGFR-Positive NSCLC: MARIPOSA and FLAURA2

Joshua Sabari, MDDanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MDAlexander Spira, MD, PhD, FACP, FASCO

EGFR+ NSCLC metastatic cancer research researchers Dr. Joshua Sabari Dr. Danny Nguyen Dr. Eric Singhi Dr. Alexander Spira Dr. Edgardo Santos oncology clinical insights oncology updates.

Lung Cancer

12/16/2025

Clinical Insights: Metastatic EGFR+ NSCLC from MARIPOSA and PALOMA-3

Joshua Sabari, MDAlexander Spira, MD, PhD, FACP, FASCODanny Nguyen, MDEdgardo Santos Castillero, MD, FACP, FASCOEric Singhi, MD

In-depth analysis of key insights from IMforTe regarding treating ES-SCLC with expert clinicians Dr. Stephen Liu, Dr. Ticiana Leal, Dr. Isabel Preeshagul, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Lung Cancer

10/19/2025

EP. 6: Key Takeaways From IMforte for Clinicians Treating ES-SCLC

Ticiana Leal, MDStephen Liu, MDIsabel Preeshagul, DO, MBSRahul Gosain, MD, MBARohit Gosain, MD

Sequencing Lurbinectedin in ES-SCLC with CNS Involvement - OncUpdates featuring Dr. Stephen Liu, Dr. Ticiana Leal, Dr. Rahul Gosain, and Dr. Rohit Gosain focusing on recent advancements in small cell lung cancer treatment.

Lung Cancer

10/17/2025

EP. 5: Sequencing Lurbinectedin in ES-SCLC with CNS Involvement

Ticiana Leal, MDStephen Liu, MDRahul Gosain, MD, MBARohit Gosain, MD

Lurinctedin adverse events management in ES-SCLC maintenance therapy with expert doctors Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Isabel Preeshagul, and Dr. Stephen Liu, from OncUpdates.

Lung Cancer

10/15/2025

EP. 4: Managing Lurbinectedin Adverse Events in ES-SCLC Maintenance Therapy

Isabel Preeshagul, DO, MBSStephen Liu, MDRahul Gosain, MD, MBARohit Gosain, MD

Immunotherapy and clinical research experts discussing the clinical relevance of IMforTE survival data in ES-SCLC. Featuring Dr. Ticiana Leal, Dr. Stephen Liu, Dr. Rahul Gosain, and Dr. Rohit Gosain at OncUpdates.

Lung Cancer

10/13/2025

Ep. 3: Clinical Relevance of IMforte Survival Data in ES-SCLC

Ticiana Leal, MDStephen Liu, MDRahul Gosain, MD, MBARohit Gosain, MD

Efficacy outcomes in the IMforte trial featuring Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Stephen Liu, highlighting PFS, OS, and clinical impact for cancer treatment advancements.

Lung Cancer

10/11/2025

Ep. 2: Efficacy Outcomes in the IMforte Trial: PFS, OS, and Clinical Impact

Stephen Liu, MDRahul Gosain, MD, MBARohit Gosain, MD

IMforte Study Design and Maintenance Approach in ES-SCLC

Lung Cancer

10/10/2025

Ep. 1: IMforte Study Design and Maintenance Approach in ES-SCLC

Isabel Preeshagul, DO, MBSRahul Gosain, MD, MBARohit Gosain, MD

Lurbinectedin first-line maintenance therapy for small cell lung cancer, featuring expert oncologists discussing extensive-stage treatment options and latest research.

Lung Cancer

10/06/2025

IMforte: Maintenance With Lurbinectedin in Newly Diagnosed ES-SCLC (Full Video)

Rohit Gosain, MDRahul Gosain, MD, MBAStephen Liu, MDTiciana Leal, MDIsabel Preeshagul, DO, MBS

Innovative oncology discussion featuring medical experts sharing insights on cancer treatment strategies at OncUpdates conference.

Lung Cancer

06/16/2025

Ep. 3: How to Choose the Best First-Line Therapy for Patients With EGFR-Mutated NSCLC

Susan Scott, MDEstelamari Rodriguez, MD, MPHHelena Yu, MD

Expert medical panel discussion on cancer updates and new treatment strategies at OncUpdates.

Lung Cancer

06/16/2025

Ep. 2: New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC

Helena Yu, MDJoshua Sabari, MD

Doctor and patient discussion about cancer treatment at OncUpdates conference, emphasizing oncology care and medical research.

Lung Cancer

06/16/2025

EP. 1: Targeted Therapies in EGFR-Mutated NSCLC: Managing Treatment-Related AEs

Estelamari Rodriguez, MD, MPHHelena Yu, MDJoshua Sabari, MD

Mariposa: Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC - Oncology research featuring leading doctors discussing advanced lung cancer treatment options and targeted therapies.

Lung Cancer

06/15/2025

MARIPOSA: Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC

Estelamari Rodriguez, MD, MPHHelena Yu, MDJoshua Sabari, MDSusan Scott, MDRahul Gosain, MD, MBARohit Gosain, MD